Chemical Formula: C26H54NO7P
Chemical Formula C26H54NO7P
Found 63 metabolite its formula value is C26H54NO7P
LysoPC(0:0/18:0)
LysoPC(0:0/18:0) or LPC(0:0/18:0) is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. There is also a phospholipase A1, which is able to cleave the sn-1 ester bond. Lysophosphatidylcholine has pro-inflammatory properties in vitro and it is known to be a pathological component of oxidized lipoproteins (LDL) in plasma and of atherosclerotic lesions. Recently, it has been found to have some functions in cell signalling, and specific receptors (coupled to G proteins) have been identified. It activates the specific phospholipase C that releases diacylglycerols and inositol triphosphate with resultant increases in intracellular Ca2+ and activation of protein kinase C. It also activates the mitogen-activated protein kinase in certain cell types.LysoPC(0:0/18:0) has been shown to be protective against lethal sepsis in experimental animals by various mechanisms, including stimulation of neutrophils to eliminate invading pathogens through a peroxide-dependent reaction. LysoPC(0:0/18:0) or LPC(0:0/18:0) is a lysophospholipid (LPL). LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. LysoPC(0:0/18:0) has been shown to be protective against lethal sepsis in experimental animals by various mechanisms, including stimulation of neutrophils to eliminate invading pathogens through a peroxide-dependent reaction. [HMDB]
LysoPC(18:0/0:0)
LysoPC(18:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:0), in particular, consists of one chain of stearic acid at the C-1 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(18:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(18:0), in particular, consists of one chain of stearic acid at the C-1 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
Platelet-activating factor
Platelet-activating factor, also known as PAF and PC(O-16:0/2:0), is a ubiquitous, potent phospholipid activator and mediator of inflammation that has an important role in the pathogenesis of inflammatory disorders and cardiovascular disease. PAF is able to cause platelet aggregation and anaphylaxis. PAF is synthesized continuously in low quantities in many different types of cells, but especially those involved in host defence, such as macrophages, monocytes, granulocytes, neutrophils, platelets, and endothelial cells. Platelet-activating factor receptor (PAFR) is a G-protein coupled receptor (GPCR) located on the cell membranes of a variety of cells. Once bound to its receptor, PAF mobilizes calcium and activates a wide range of signalling pathways (e.g. phospholipase C-mediated signalling (PMID: 26616844). C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability[1][2][3][4][5].
2-Lysophosphatidylcholine
C16-PAF
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability[1][2][3][4][5].
LPC 18:0
CONFIDENCE standard compound; INTERNAL_ID 258
Lyso-PC 18:0
MALDI generates [M+H]+ ion, which is dissociated by the reaction with 3O (triplet O) generated by O2 microwave discharge (RID).; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data and fragment ions produced are shown in Figure S6_1 of the publication.; Relative intensity of the peaks m/z 180-199 are magnified by x5, those of the peaks m/z 200-507 by x100.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL). MALDI generates a stable [M+H]+ ion. Microwave discharge of H2O generates OH*, H* and 3O (triplet O) radicals. These radicals react with the stable [M+H]+ ion and give a mixture of [M+H+H*], [M+H+O]+ and [M+H+OH*]+ ions. These are dissociated to give product ions, which are detected as RID product ions.; The instrument consists of QIT-TOF where Q selects [M+H]+ ion, IT is an ion trap chamber for the reaction of RID, and TOF analyzes the product ions.; This mass spectral data is shown in Figure S5 of the publication. Fragment ions produced are annotated in Scheme 2 of the publication.; Relative Intensity is magnified; m/z 166-190 by x5, m/z 200-510 by x100.; The sample was injected by direct infusion of methanol solution.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 19HP8024 to the Mass Spectrometry Society of Japan.; The lipid standard was purchased from Avanti Polar Lipids (Alabaster, AL).
Platelet-activating factor
PC(2:0/O-16:0)[U]
PC(18:0/0:0)[S]
PC(0:0/18:0)
PC(0:0/18:0)[S]
1-O-HEXADECYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE
(2-Acetyloxy-3-hexadecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] henicosanoate
(2-Decanoyloxy-3-octoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(2-Nonanoyloxy-3-nonoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] tridecanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] octanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] dodecanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] hexanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] nonanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] butanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonadecoxypropan-2-yl] acetate
(3-Dodecoxy-2-hexanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(2-Heptanoyloxy-3-undecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(2-Pentanoyloxy-3-tridecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(3-Pentadecoxy-2-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(3-Decoxy-2-octanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] undecanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] decanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octadecoxypropan-2-yl] propanoate
(2-Butanoyloxy-3-tetradecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] heptanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] pentanoate
2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine
A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine betaine which has hexadecyl as the alkyl group. PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
1-Stearoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:0 in which the acyl substituent is located at position 1 and is specified as stearoyl.
lysophosphatidylcholine 18:0
A lysophosphatidylcholine in which the acyl group has a fully saturated C18 chain and is attached to the glycero moiety at either position 1 or 2.
Lysophosphatidylcholine(0:0/18:0)
A 2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group contains 18 carbons and is fully saturated.
Lysophosphatidylcholine(18:0/0:0)
A 1-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group contains 18 carbons and is fully saturated.
2-stearoyl-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 18:0 in which the acyl group is specified as stearoyl (octadecanoyl) and is located at position 2.
MePC(17:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PE(21:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved